GEN 1059
Alternative Names: BNT 314; GEN-1059Latest Information Update: 11 Dec 2023
At a glance
- Originator BioNTech; Genmab
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 01 Dec 2023 BioNTech plans a phase I/II trial for Solid tumours (Monotherapy, Combination therapy, Late-stage disease, First-line therapy) in USA (IV, Infusion) (NCT06150183)
- 30 Nov 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) in USA (IV)
- 30 Nov 2023 Phase-I/II clinical trials in Solid tumours (Monotherapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT06150183)